Lower levels of AngII in the brain have a protective effect on the development of obesity and the related metabolic impairments in rats fed HFDs; hence, RAS blockers were proposed as a pharmacological treatment for obesity [32]. Here, AGT is linked to obesity due to melanocortin 4 receptor deficiency.